Three patients had KRAS wild-type (WT) tumor in the primary tissue and KRAS mutant (MT) tumor (two patients had KRASG12A and one patient had KRASG13D mutations) in the metastatic tissue. This evidence concerns the gene KRAS and neoplasm.